Mirum Pharmaceuticals Inc (MIRM) - Net Assets
Based on the latest financial reports, Mirum Pharmaceuticals Inc (MIRM) has net assets worth $242.49 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($890.92 Million) and total liabilities ($648.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check MIRM cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $242.49 Million |
| % of Total Assets | 27.22% |
| Annual Growth Rate | N/A |
| 5-Year Change | 161.78% |
| 10-Year Change | N/A |
| Growth Volatility | 33.98 |
Mirum Pharmaceuticals Inc - Net Assets Trend (2018–2025)
This chart illustrates how Mirum Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore Mirum Pharmaceuticals Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Mirum Pharmaceuticals Inc (2018–2025)
The table below shows the annual net assets of Mirum Pharmaceuticals Inc from 2018 to 2025. For live valuation and market cap data, see market value of Mirum Pharmaceuticals Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $314.69 Million | +39.47% |
| 2024-12-31 | $225.64 Million | -9.26% |
| 2023-12-31 | $248.67 Million | +75.07% |
| 2022-12-31 | $142.04 Million | +18.16% |
| 2021-12-31 | $120.21 Million | -30.15% |
| 2020-12-31 | $172.09 Million | +32.03% |
| 2019-12-31 | $130.35 Million | +1362.70% |
| 2018-12-31 | $-10.32 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mirum Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 65019600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $351.00K | 0.11% |
| Other Components | $981.88 Million | 312.01% |
| Total Equity | $314.69 Million | 100.00% |
Mirum Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Mirum Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenghe Resources Holding Co Ltd
SHG:600392
|
$6.03 Billion |
|
YTL Corporation Bhd
KLSE:4677
|
$6.03 Billion |
|
Guangzhou Friendship Group Co Ltd
SHE:000987
|
$6.03 Billion |
|
BOC Aviation Limited
F:8BO
|
$6.04 Billion |
|
Shanghai Commercial & Savings Bank Ltd
TW:5876
|
$6.03 Billion |
|
Hyundai Mipo Dockyard
KO:010620
|
$6.03 Billion |
|
Bachem Holding AG
SW:BANB
|
$6.02 Billion |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
$6.02 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mirum Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 225,640,000 to 314,690,000, a change of 89,050,000 (39.5%).
- Net loss of 23,363,000 reduced equity.
- Other comprehensive income increased equity by 724,000.
- Other factors increased equity by 111,689,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-23.36 Million | -7.42% |
| Other Comprehensive Income | $724.00K | +0.23% |
| Other Changes | $111.69 Million | +35.49% |
| Total Change | $- | 39.47% |
Book Value vs Market Value Analysis
This analysis compares Mirum Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.78x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.45 | $98.90 | x |
| 2019-12-31 | $5.67 | $98.90 | x |
| 2020-12-31 | $6.82 | $98.90 | x |
| 2021-12-31 | $3.96 | $98.90 | x |
| 2022-12-31 | $4.18 | $98.90 | x |
| 2023-12-31 | $6.08 | $98.90 | x |
| 2024-12-31 | $4.75 | $98.90 | x |
| 2025-12-31 | $6.27 | $98.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mirum Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.48%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 2.68x
- Recent ROE (-7.42%) is above the historical average (-47.23%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.32 Million |
| 2019 | -40.32% | 0.00% | 0.00x | 1.13x | $-65.59 Million |
| 2020 | -60.01% | -938.82% | 0.05x | 1.40x | $-120.48 Million |
| 2021 | -69.87% | -438.85% | 0.06x | 2.45x | $-96.01 Million |
| 2022 | -95.51% | -176.05% | 0.22x | 2.48x | $-149.87 Million |
| 2023 | -65.72% | -87.68% | 0.29x | 2.60x | $-188.28 Million |
| 2024 | -38.97% | -26.10% | 0.50x | 2.97x | $-110.51 Million |
| 2025 | -7.42% | -4.48% | 0.62x | 2.68x | $-54.83 Million |
Industry Comparison
This section compares Mirum Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $190,374,900
- Average return on equity (ROE) among peers: -53.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mirum Pharmaceuticals Inc (MIRM) | $242.49 Million | 0.00% | 2.67x | $6.03 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $91.45 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $312.29 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $174.79 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $823.18 Million |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $10.00K | -200.00% | 3.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $540.89 Million | -31.04% | 0.29x | $3.64 Billion |
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille … Read more